In the ovary it has been demonstrated that PGF 2␣ activates the phospholipase C (PLC)/diacylglycerol/protein kinase C pathway. However, little is known about the downstream signaling events that mediate subsequent cellular responses such as steroidogenesis. The present study was designed to examine the effect of PGF 2␣ on activation of the mitogen-activated protein kinase (MAPK) signaling pathway and its physiological role in human granulosa-luteal cells (hGLCs). Human GLCs, obtained from women undergoing in vitro fertilization-embryo transfer, were treated with increasing concentrations of PGF 2␣ (10 nmol/L to 10 mol/L) for 5 min. For time-course experiments, hGLCs were treated with 1 mol/L PGF 2␣ for 1, 5, 10, or 20 min. Western blot analysis, using a monoclonal antibody that detected the phosphorylated forms of extracellular signal-regulated kinases 1 and 2 (p42 mapk and p44 mapk , respectively), demonstrated that PGF 2␣ activated MAPK in hGLCs in a dose-and time-dependent manner. Treatment of the cells with neomycin (10 mmol/L; a PLC inhibitor), bisindolylmaleimide I (5 mol/L; a PKC inhibitor), or PD98059 (50 mol/L; a MEK inhibitor and a MAPK kinase inhibitor) significantly attenuated the PGF 2␣ -induced activation of MAPK. In contrast, MAPK activation was not significantly affected by pertussis toxin (200 ng/mL; a G i inhibitor) pretreatment. To determine the role of MAPK in steroidogenesis, hGLCs were treated with PGF 2␣ (1 mol/ L), hCG (1 IU/mL), or PGF 2␣ plus hCG in the presence or absence of PD98059. Progesterone levels in the culture medium were examined by RIA. Treatment of hGLCs with PGF 2␣ significantly inhibited hCGinduced progesterone production. The presence of the MEK inhibitor, PD98059, reversed the inhibitory effect of PGF 2␣ on hCG-induced progesterone production. To our knowledge, it is the first demonstration of PGF 2␣ -induced activation of the MAPK signaling pathway in the human ovary. These results indicated that PGF 2␣ activated MAPK subsequent to PLC and PKC activation through pertussis toxin-insensitive G protein in hGLCs. Further, we demonstrated that PGF 2␣ -induced MAPK activation is associated with modulation of progesterone production. These results support the idea that the MAPK signaling pathway is involved in mediating PGF 2␣ actions in the human ovary. (J Clin Endocrinol Metab 86: 375-380, 2001) 
significantly attenuated the PGF 2␣ -induced activation of MAPK. In contrast, MAPK activation was not significantly affected by pertussis toxin (200 ng/mL; a G i inhibitor) pretreatment. To determine the role of MAPK in steroidogenesis, hGLCs were treated with PGF 2␣ (1 mol/ L), hCG (1 IU/mL), or PGF 2␣ plus hCG in the presence or absence of PD98059. Progesterone levels in the culture medium were examined by RIA. Treatment of hGLCs with PGF 2␣ significantly inhibited hCGinduced progesterone production. The presence of the MEK inhibitor, PD98059, reversed the inhibitory effect of PGF 2␣ on hCG-induced progesterone production. To our knowledge, it is the first demonstration of PGF 2␣ -induced activation of the MAPK signaling pathway in the human ovary. These results indicated that PGF 2␣ activated MAPK subsequent to PLC and PKC activation through pertussis toxin-insensitive G protein in hGLCs. Further, we demonstrated that PGF 2␣ -induced MAPK activation is associated with modulation of progesterone production. These results support the idea that the MAPK signaling pathway is involved in mediating PGF 2␣ actions in the human ovary. (J Clin Endocrinol Metab 86: 375-380, 2001) P GF2␣ HAS BEEN implicated in the regression of the mammalian corpus luteum (1) (2) (3) (4) . PGF 2␣ activates the phospholipase C (PLC)/diacylglycerol/protein kinase C (PKC) pathway to regulate ovarian function (5) (6) (7) (8) (9) (10) . Through this signaling pathway, PGF 2␣ is capable of inhibiting gonadotropin-stimulated progesterone production (11) .
Mitogen-activated protein kinases (MAPKs) are a group of serine-threonine kinases involved in converting extracellular stimuli to intracellular signals. Extracellular signal-regulated kinases (ERK), one of MAPKs subfamilies, are proteinserine/threonine kinases that are activated by extracellular agonists such as cytokines, growth factors, and neurotransmitters (12, 13) . Two distinct classes of cell surface receptors, G protein-coupled receptor and receptor tyrosine kinases, have been shown to activate the MAPKs (14 -16) . When activated, ERK1 and ERK2 (also known as p42 mapk and p44 mapk , respectively), phosphorylate a variety of substrates, including nuclear transcript factors, which have been implicated in the control of cell proliferation and differentiation (17) (18) (19) .
PGF 2␣ stimulates the MEK1/MAPK signaling cascade in bovine luteal cells (20) . However, the physiological role of MAPK in luteal cells is still poorly understood. PGF 2␣ receptor has been reported to be expressed in human granulosa-luteal cells (hGLCs) (21) , but little is known about the signaling events subsequent to the binding of PGF 2␣ to its receptor in hGLCs. In the present study the ability of PGF 2␣ to activate MAPK was investigated in cultured hGLCs. In addition, potential involvement of MAPK in PGF 2␣ -induced antigonadotropic action was examined.
Materials and Methods

Reagents and materials
PGF 2␣ , pertussis toxin (PTX), neomycin and hCG were obtained from Sigma (St. Louis, MO). Bisindolylmaleimide I, a PKC inhibitor, was obtained from Calbiochem (Cedarlane, Canada). PD98059, a MEK inhibitor, was purchased from New England Biolabs, Inc. (Beverly, MA). DMEM, penicillin-streptomycin, and FBS were obtained from Life Technologies, Inc. (Burlington, Canada). Bisindolylmaleimide I and PD98059 were dissolved in dimethylsulfoxide as suggested by the manufacturers.
Human GLC culture
Human GLCs were collected from patients undergoing an in vitro fertilization-embryo transfer program. The use of human GLCs was approved by the University of British Columbia clinical screening committee for research and other studies involving human subjects. Granulosa cells were separated from red blood cells in follicular aspirates by centrifugation through Ficoll-Paque, washed, and suspended in DMEM containing 100 U penicillin G/mL, 100 g streptomycin/mL, and 10% FBS as described previously (10) . The cells were plated at a density of approximately 150,000 cells in 35-mm culture dishes. The dishes were incubated at 37 C under a water-saturated atmosphere of 5% CO 2 in air for 3 days.
Treatments
Human GLCs were incubated in serum-free medium for 4 h before treatment. To examine the dose effect, hGLCs were treated with increasing concentrations of PGF 2␣ (10 nmol/L, 100 nmol/L, 1 mol/L, or 10 mol/L) for 5 min. For time-course experiments, hGLCs were treated with 1 mol/L PGF 2␣ for 1, 5, 10, or 20 min.
To examine the intracellular signaling pathway subsequent to PGF 2␣ treatment, hGLCs were treated with PTX (200 ng/mL), neomycin (10 mmol/L; a PLC inhibitor), bisindolylmaleimide I (5 mol/L; a PKC inhibitor), or PD98059 (50 mol/L; a MEK inhibitor) in the presence or absence of PGF 2␣ . In the present study hGLCs were pretreated with PTX for 1 h, with neomycin for 15 min, with bisindolylmaleimide I for 10 min, and with PD98059 for 1 h before PGF 2␣ treatment. The cells were collected 5 min after PGF 2␣ exposure.
Western blot analysis
The granulosa cells were washed with ice-cold PBS and incubated in 100 L cell lysis buffer (150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 7.5), 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 1.0 mmol/L phenylmethylsulfonylfluoride, 10 g/mL leupeptin, and 100 g/mL aprotinin) at 4 C for 30 min. The cell lysate was centrifuged at 10,000 ϫ g for 5 min, and the supernatant was collected for Western blot analysis. The amount of protein was quantified using the Bio-Rad Laboratories, Inc., protein assay kit (Bio-Rad Laboratories, Inc., Richmond, CA) following the manufacturer's protocol. Aliquots (30 g) were subjected to 10% SDS-PAGE under reducing conditions, as previously described (22) . The proteins were then electrophoretically transferred from the gels onto nitrocellulose membranes (Amersham Pharmacia Biotech, Ontario, Canada) according to the procedures of Towbin et al. (23) . These nitrocellulose membranes were probed with a mouse monoclonal antibody directed against the phosphorylated forms of ERK1 and ERK2 (P-MAPK, p42 mapk and p44 mapk , respectively) at 4 C for 16 h. Alternatively, the membranes were probed with a rabbit polyclonal antibody for p42/p44 MAPK, which detected total MAPK (T-MAPK) levels (New England Biolabs, Inc.). After washing, these membranes were incubated with horseradish peroxidase-conjugated goat antimouse secondary antibody. The Amersham Pharmacia Biotech ECL system (Amersham Pharmacia Biotech) was used to detect the signal. Finally, these membranes were exposed to x-ray film (Kodak Omat x-ray film, Eastman Kodak Co., Rochester, NY). The autoradiograms were scanned with a laser densitometer (model 620 video densitometer, Bio-Rad Laboratories, Inc., Richmond, CA).
RIA
After culture in DMEM with 10% FBS for 3 days, hGLCs were incubated in DMEM with 5% FBS for 4 h before treatment for steroidogenesis experiments. To determine the role of MAPK in steroidogenesis, hGLCs were treated with PGF 2␣ (1 mol/L), hCG (1 IU/mL), or PGF 2␣ plus hCG in the presence or absence of PD98059 for 24 h (24) .
Progesterone levels in the culture medium were measured by established RIA (25) . Antiprogesterone antibody was provided by Dr. D. T. Armstrong (University of Western Ontario). Briefly, samples were incubated with antibody and tracer, with a final concentration of 7000 cpm/mL of [1,2,6,7,16,17- 3 H]progesterone (Amersham Pharmacia Biotech). After incubation for 16 -24 h, a charcoal/dextran solution was added to remove unbound progesterone or tracer. Scintillation cocktail (Amersham Pharmacia Biotech) was added to each sample, and the vials were counted with a ␤-counter (LKB Wallac, Inc., Turku, Finland). The cells in each dish were harvested for quantifying protein amount using a protein assay kit (Bio-Rad Laboratories, Inc.). Samples were assayed in triplicate, and progesterone concentrations were standardized against total protein content.
hCG and MAPK in hGLCs
Gonadotropins have been demonstrated to activate MAPK in porcine granulosa cells (26) . To examine the effect of hCG on MAPK activation, hGLCs were treated with 1 IU/mL hCG for 1, 5, 10, or 20 min, and cell lysates were collected for Western blot analysis. The effect of MAPK on hCG-stimulated progesterone production was studied by treating cells with 1 IU/mL hCG in the presence or absence of PD98059 for 24 h.
Statistical analysis
MAPK activity and progesterone levels were expressed as a relative ratio of basal levels. Data are shown as the mean Ϯ se. Statistical analysis was performed by one-way ANOVA followed by Tukey's multiple comparison test. Differences were considered significant at P Ͻ 0.05.
Results
Effects of PGF 2␣ on MAPK activation
To demonstrate the ability of PGF 2␣ in activating MAPK, hGLCs were treated with increasing concentrations (10 nmol/L to 10 mol/L) of PGF 2␣ for 5 min. For time-course analysis, the cells were treated with 1 mol/L PGF 2␣ for varying time intervals (1-20 min). As shown in Fig. 1 , PGF 2␣ activated MAPK in hGLCs in a dose-dependent manner. A significant effect was observed at 100 nmol/L, and a maximum effect was noted at 10 mol/L. PGF 2␣ was capable of rapidly inducing MAPK activity. A significant effect was seen 5 min after treatment (Fig. 2) . 2␣ to MAPK activation in hGLCs. Human GLCs were treated with increasing concentrations of PGF 2␣ (0, 10 nmol/L, 100 nmol/L, 1 mol/L, or 10 mol/L) for 5 min as described in Materials and Methods. The activated MAPK was detected by Western blot analysis. The data were shown as relative ratio to basal levels. Values were presented as the mean Ϯ SE of three individual experiments. Statistical analysis was performed by oneway ANOVA followed by Tukey's test. Differences were considered significant at P Ͻ 0.05 (*).
FIG. 1. The dose-response of PGF
PTX and PGF 2␣ -induced MAPK activation
PGF 2␣ binds to a G protein-coupled transmembrane receptor in hGLCs (10) . A PTX-insensitive G protein-coupled, G q/11 ␣, is known to be expressed in hGLCs (10, 27) . To identify the subclass of G protein involved in the PGF 2␣ -induced activation of MAPK, human GLCs were pretreated with PTX for 1 h before exposure to PGF 2␣ . In the present study pretreatment of PTX did not alter PGF 2␣ -induced MAPK activity, indicating that PGF 2␣ acts through a PTXinsensitive G protein-coupled receptor (Fig. 3) . Pretreatment with PTX for 24 h did not change the result, and PTX had no effect on PGF 2␣ -induced MAPK activation up to 500 ng/mL (data not shown).
PLC and PGF 2␣ -induced MAPK activation
Extracellular stimuli such as hormone, growth, and neurotransmitters cause the hydrolysis of phosphatidylinositol bisphosphate via the activation of PLC, resulting in the production of inositol triphosphate (IP3) and diacylglycerol (DAG). Neomycin, an aminoglycoside antibiotic, has been demonstrated to inhibit PLC (28) . As shown in Fig. 4 , treatment of hGLCs with 10 mmol/L neomycin significantly inhibited the PGF 2␣ -induced activation of MAPK. PGF 2␣ activated MAPK to about 330% of the basal (control) level. The combined treatment with neomycin and PGF 2␣ significantly reduced MAPK activity by 80% compared with PGF 2␣ treatment alone.
PKC and PGF 2␣ -induced MAPK activation
DAG alone or with cytosolic Ca 2ϩ , mobilized by IP3, plays a role in activating PKC. Bisindolylmaleimide I is a selective inhibitor of PKC (29) . In this study bisindolylmaleimide I significantly attenuated the PGF 2␣ -induced activation of MAPK (Fig. 5 ). Concomitant treatment with the PKC inhibitor and PGF 2␣ attenuated MAPK activation by 60% compared with the level stimulated by PGF 2␣ alone. 
MEK and PGF 2␣ -induced MAPK activation
In MAPK activation cascade, MEK is the immediate activator of MAPK. MEK is also named MAPK kinase (13) . In the present study it was shown that the MEK inhibitor, PD98059, significantly decreased the PGF 2␣ -induced activation of MAPK in hGLCs (Fig. 6) . Cotreatment with PD98059 and PGF 2␣ reduced MAPK activity to 15% of the level stimulated by PGF 2␣ alone.
Effects of PGF 2␣ -evoked MAPK activation of hCG-induced progesterone production
To determine the role of MAPK in ovarian steroidogenesis, hGLCs were treated with PGF 2␣ (1 mol/L), hCG (1 IU/mL), or PGF 2␣ plus hCG in the presence or absence of PD98059. As shown in Fig. 7 and 1 mol/L PGF 2␣ had no effect on the basal level of progesterone production, whereas hCG increased progesterone production to 220% of the control value in hGLCs. Cotreatment of hGLCs with PGF 2␣ and hCG significantly inhibited progesterone production to 40% of the level induced by hCG. Further, the presence of the MEK inhibitor (PD98059) affected the inhibitory effect of PGF 2␣ on hCG-induced progesterone production.
hCG activates MAPK in hGLCs
As shown in Fig. 8A , hCG was capable of activating MAPK in hGLCs in a time-dependent manner. Phosphorylated MAPK increased significantly in 1 min, compared with the control, and reached a maximum response after treatment with 1 IU/mL hCG for 5 min. To investigate the role of hCG-stimulated MAPK in steroidogenesis, hGLCs were treated with hCG in the presence or absence of MEK inhibitor. RIA demonstrated that there was no significant effect of MEKI on hCG-induced progesterone production (Fig. 8B) .
Discussion
A diverse array of ligands, including hormones, neurotransmitters, and growth factors, are able to activate MAPK. Thus, cells may contain several MAPK signaling cascades, potentially regulated independently (30) . MAP kinases are classified into three subfamilies: I) ERKs, including ERK1 and ERK2; II) stress-activated protein kinases, also called c-jun N-terminus kinases; and III) p38 kinase (15) . The first MAPKs to be cloned were MAPK/ERK1 and -2 (ERK1/2) (31, 32). In regard to regulation of the MAPK family mem- bers, the MEK known as MAPK kinases (MAPKKs) activate MAPKs by phosphorylating tyrosine and threonine residues (13) . MAP kinases have been identified in several steroidogenic cells. For example, an immunocytochemistry study has indicated that MAP kinase is localized in the zona glomerulosa and the medulla of the rat adrenal gland (33) . Angiotensin II, which stimulates steroidogenesis in bovine adrenocortical cells through the phosphoinositides pathway activates ERK1 and ERK2 (16) . PGF 2␣ has been demonstrated to stimulate the MEK1/MAPK signaling cascade in bovine luteal cells (20) . However, knowledge about MAPK in human ovary is still limited. Recently, Kang et al. reported that MAPKs mediate the inhibitory effect of GnRH on progesterone production in hGLCs (24) , indicating the role of MAPKs in steroidogenesis. In the present study the phosphospecific MAPK antibody, which detected phosphorylated Thr 202 and Tyr 204 , was used to measure activated MAPK by Western blot analysis. We demonstrated that PGF 2␣ activates MAPK in hGLCs, an effect that is dose and time dependent. Further, our results clearly show that the PGF 2␣ -activated MAPK is linked with alterations in steroidogenesis in hGLCs.
The human ovary has been reported to produce PGF 2␣ (34) , which has been suggested to mediate luteal regression in the mammalian ovary (3, 4) . PGF 2␣ has been shown to inhibit LH-and hCG-induced progesterone production (11, 25) . Several studies demonstrate that the luteolytic effect of PGF 2␣ is through increasing the production of endothelin-1, which, in turn, inhibits luteal steroidogenesis and induces the release of tumor necrosis factor-␣, a proapoptotic factor (35) (36) (37) . In addition, tumor necrosis factor-␣ was found to increase PGF 2␣ production in human granulosa cells (38) . In the present study it was demonstrated that MAPK may mediate the inhibitory effect of PGF 2␣ on hCG-induced progesterone production.
After binding to transmembrane receptor, PGF 2␣ has been shown to activate phospholipase C through PTX-resistant G protein in hGLCs (10) , resulting in the production of IP3 and DAG, which, in turn, activates PKC. In the present study PGF 2␣ -induced phosphorylation of MAPK was not effected by 200 ng/mL PTX, implicating the involvement of a PTXinsensitive G protein such as G q/11 ␣ (10). Both PLC␤ and PLC␥ isoforms have been identified in hGLCs. Activation of the PGF 2␣ receptor has been reported to couple to PLC␤ (10) . Neomycin has been demonstrated to inhibit all three isoforms of PLCs (28) and PGF 2␣ -induced cellular responses such as vessel contraction (39) . In the present study 10 mmol/L neomycin significantly attenuates the phosphorylated forms of MAPK, demonstrating the involvement of PLC in PGF 2␣ -induced MAPK activation. In addition, PGF 2␣ has been reported to activate PKC and induce cytosolic calcium oscillations in human ovarian cells (8, 9) . Via the activation of PKC, PGF 2␣ is known to exert antigonadotropic action by either reducing cAMP accumulation or stimulating cAMP phosphodiesterase (8, 11, 40) . Bisindolylmaleimide is a selective inhibitor of PKC (29) . In this study PGF 2␣ -induced MAPK activation was significantly attenuated in hGLCs pretreated with this PKC inhibitor. MEK, also known as MAPK kinase (13) , is an immediate activator of MAPK. In this study the presence of the MEK inhibitor, PD98059, significantly decreased the PGF 2␣ -induced activation of MAPK. Taken together, the results of the present study clearly demonstrate the activation of the MAPK cascade by PGF 2␣ in hGLCs.
In hGLCs, the effect of PGF 2␣ on steroidogenesis is somewhat inconsistent (25, 41, 42) . In this study 1 mol/L PGF 2␣ had no effect on steroidogenesis in hGLCs. By contrast, treatment of hGLCs with PGF 2␣ significantly inhibited the progesterone production induced by hCG. The observation that PGF 2␣ inhibited gonadotropin-induced progesterone production has been shown previously (8, 11, 38) . It has been proposed that the antigonadotropic action of PGF 2␣ is exerted via the inhibition of cAMP production. Further, PKC has been demonstrated to play a mediatory role in the inhibitory effect of PGF 2␣ on hCG-induced progesterone production in hGLCs (11) . In the present study we demonstrated that the inhibitory effect of PGF 2␣ was reversed by MEK inhibitor, implicating a role of MAPK in the antigonadotropic action of PGF 2␣ in hGLCs. Oliver et al. reported that PD98059 (100 mol/L) induced apoptosis in luteinized granulosa cells cultured in serum-free medium (43) . We observed hGLCs to be viable and have no morphological change after 24-h treatment with PD98059 in DMEM supplemented with 5% FBS. The precise mechanism by which MAPKs affect ovarian steroid hormone is not clear. Several steroidogenic proteins or enzymes, such as steroidogenic acute regulatory protein, cytochrome P450 cholesterol side-chain cleavage, and 3␤-hydroxysteroid dehydrogenase, have been demonstrated in the human ovary (44, 45) . Considering the nuclear translocation of activated MAPKs (7, 11-13), it can be pos- LH has been demonstrated to increase MAPK activity in porcine granulosa cells (26) . In the present study hCG activated both ERK1 and ERK2 in a time-dependent manner. However, the hCG-induced MAPK did not alter hCG-stimulated progesterone production. Taken together, these observations support the idea that a diverse array of ligands, including hormones, neurotransmitters, and growth factors, are able to activate MAPK, and that cells may contain several MAPK signaling cascades, potentially regulated independently (30) .
To our knowledge, it is the first demonstration of PGF 2␣ -induced activation of the MAPK signaling pathway in the human ovary. Our data indicated that binding of PGF 2␣ to its receptor couples to a PTX-insensitive G protein-coupled, which subsequently leads to PLC, PKC, and MAPK activation. Further, we demonstrated that inhibition of MAPK activation reverses the effect of PGF 2␣ on progesterone production. These results support the hypothesis that the MAPK cascade is an integral part of the PGF 2␣ signal transduction system in the human ovary.
